177 related articles for article (PubMed ID: 19075603)
1. Optimization and validation of two miniaturized glucocerebrosidase enzyme assays for high throughput screening.
Urban DJ; Zheng W; Goker-Alpan O; Jadhav A; Lamarca ME; Inglese J; Sidransky E; Austin CP
Comb Chem High Throughput Screen; 2008 Dec; 11(10):817-24. PubMed ID: 19075603
[TBL] [Abstract][Full Text] [Related]
2. A high throughput glucocerebrosidase assay using the natural substrate glucosylceramide.
Motabar O; Goldin E; Leister W; Liu K; Southall N; Huang W; Marugan JJ; Sidransky E; Zheng W
Anal Bioanal Chem; 2012 Jan; 402(2):731-9. PubMed ID: 22033823
[TBL] [Abstract][Full Text] [Related]
3. High throughput screening for small molecule therapy for Gaucher disease using patient tissue as the source of mutant glucocerebrosidase.
Goldin E; Zheng W; Motabar O; Southall N; Choi JH; Marugan J; Austin CP; Sidransky E
PLoS One; 2012; 7(1):e29861. PubMed ID: 22272254
[TBL] [Abstract][Full Text] [Related]
4. Identification of pharmacological chaperones for Gaucher disease and characterization of their effects on beta-glucocerebrosidase by hydrogen/deuterium exchange mass spectrometry.
Tropak MB; Kornhaber GJ; Rigat BA; Maegawa GH; Buttner JD; Blanchard JE; Murphy C; Tuske SJ; Coales SJ; Hamuro Y; Brown ED; Mahuran DJ
Chembiochem; 2008 Nov; 9(16):2650-62. PubMed ID: 18972510
[TBL] [Abstract][Full Text] [Related]
5. Inhibitor screening of pharmacological chaperones for lysosomal β-glucocerebrosidase by capillary electrophoresis.
Shanmuganathan M; Britz-McKibbin P
Anal Bioanal Chem; 2011 Mar; 399(8):2843-53. PubMed ID: 21286689
[TBL] [Abstract][Full Text] [Related]
6. Three classes of glucocerebrosidase inhibitors identified by quantitative high-throughput screening are chaperone leads for Gaucher disease.
Zheng W; Padia J; Urban DJ; Jadhav A; Goker-Alpan O; Simeonov A; Goldin E; Auld D; LaMarca ME; Inglese J; Austin CP; Sidransky E
Proc Natl Acad Sci U S A; 2007 Aug; 104(32):13192-7. PubMed ID: 17670938
[TBL] [Abstract][Full Text] [Related]
7. Fluorescent flow cytometric assay: a new diagnostic tool for measuring beta-glucocerebrosidase activity in Gaucher disease.
Rudensky B; Paz E; Altarescu G; Raveh D; Elstein D; Zimran A
Blood Cells Mol Dis; 2003; 30(1):97-9. PubMed ID: 12667991
[TBL] [Abstract][Full Text] [Related]
8. Activity-Based Probes for Glycosidases: Profiling and Other Applications.
Kuo CL; van Meel E; Kytidou K; Kallemeijn WW; Witte M; Overkleeft HS; Artola ME; Aerts JM
Methods Enzymol; 2018; 598():217-235. PubMed ID: 29306436
[TBL] [Abstract][Full Text] [Related]
9. In situ visualization of glucocerebrosidase in human skin tissue: zymography versus activity-based probe labeling.
van Smeden J; Dijkhoff IM; Helder RWJ; Al-Khakany H; Boer DEC; Schreuder A; Kallemeijn WW; Absalah S; Overkleeft HS; Aerts JMFG; Bouwstra JA
J Lipid Res; 2017 Dec; 58(12):2299-2309. PubMed ID: 29025868
[TBL] [Abstract][Full Text] [Related]
10. Hydrophilic iminosugar active-site-specific chaperones increase residual glucocerebrosidase activity in fibroblasts from Gaucher patients.
Chang HH; Asano N; Ishii S; Ichikawa Y; Fan JQ
FEBS J; 2006 Sep; 273(17):4082-92. PubMed ID: 16934036
[TBL] [Abstract][Full Text] [Related]
11. Progress and potential of non-inhibitory small molecule chaperones for the treatment of Gaucher disease and its implications for Parkinson disease.
Jung O; Patnaik S; Marugan J; Sidransky E; Westbroek W
Expert Rev Proteomics; 2016 May; 13(5):471-9. PubMed ID: 27098312
[TBL] [Abstract][Full Text] [Related]
12. Development and implementation of a miniaturized high-throughput time-resolved fluorescence energy transfer assay to identify small molecule inhibitors of polo-like kinase 1.
Sharlow ER; Leimgruber S; Shun TY; Lazo JS
Assay Drug Dev Technol; 2007 Dec; 5(6):723-35. PubMed ID: 18181689
[TBL] [Abstract][Full Text] [Related]
13. Glucocerebrosidase inhibitors for the treatment of Gaucher disease.
Trapero A; Llebaria A
Future Med Chem; 2013 Apr; 5(5):573-90. PubMed ID: 23573974
[TBL] [Abstract][Full Text] [Related]
14. A high-throughput, nonisotopic, competitive binding assay for kinases using nonselective inhibitor probes (ED-NSIP).
Vainshtein I; Silveria S; Kaul P; Rouhani R; Eglen RM; Wang J
J Biomol Screen; 2002 Dec; 7(6):507-14. PubMed ID: 14599348
[TBL] [Abstract][Full Text] [Related]
15. Development of a miniaturized 384-well high throughput screen for the detection of substrates of cytochrome P450 2D6 and 3A4 metabolism.
Kariv I; Fereshteh MP; Oldenburg KR
J Biomol Screen; 2001 Apr; 6(2):91-9. PubMed ID: 11689103
[TBL] [Abstract][Full Text] [Related]
16. Comparison of miniaturized time-resolved fluorescence resonance energy transfer and enzyme-coupled luciferase high-throughput screening assays to discover inhibitors of Rho-kinase II (ROCK-II).
Schröter T; Minond D; Weiser A; Dao C; Habel J; Spicer T; Chase P; Baillargeon P; Scampavia L; Schürer S; Chung C; Mader C; Southern M; Tsinoremas N; LoGrasso P; Hodder P
J Biomol Screen; 2008 Jan; 13(1):17-28. PubMed ID: 18227223
[TBL] [Abstract][Full Text] [Related]
17. An evolutionary and structure-based docking model for glucocerebrosidase-saposin C and glucocerebrosidase-substrate interactions - relevance for Gaucher disease.
Atrian S; López-Viñas E; Gómez-Puertas P; Chabás A; Vilageliu L; Grinberg D
Proteins; 2008 Feb; 70(3):882-91. PubMed ID: 17803231
[TBL] [Abstract][Full Text] [Related]
18. Promising results of the chaperone effect caused by imino sugars and aminocyclitol derivatives on mutant glucocerebrosidases causing Gaucher disease.
Sánchez-Ollé G; Duque J; Egido-Gabás M; Casas J; Lluch M; Chabás A; Grinberg D; Vilageliu L
Blood Cells Mol Dis; 2009; 42(2):159-66. PubMed ID: 19167250
[TBL] [Abstract][Full Text] [Related]
19. A flow cytometric assay for lysosomal glucocerebrosidase.
van Es HH; Veldwijk M; Havenga M; Valerio D
Anal Biochem; 1997 May; 247(2):268-71. PubMed ID: 9177687
[TBL] [Abstract][Full Text] [Related]
20. 2,3-di-O-tetradecyl-1-O-(beta-D-glucopyranosyl)-sn-glycerol is a substrate for human glucocerebrosidase.
Glew RH; Gopalan V; Hubbell CA; Devraj RV; Lawson RA; Diven WF; Mannock DA
Biochem J; 1991 Mar; 274 ( Pt 2)(Pt 2):557-63. PubMed ID: 1900989
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
